[1] Shore N, et al. Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia. Ther Adv Urol. 2019 Jan 14;11:1756287218820807. DOI:
10.1177/1756287218820807[2] Shore N, et al. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol. 2018 May;36(5):801-809. DOI:
10.1007/s00345-018-2185-y[3] Shore N, et al. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis. 2011 Nov;2(6):377-83. DOI:
10.1177/2040622311423128